Oculis Holding AG (OCS) Cash & Equivalents (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Cash & Equivalents of $103.9 million in Q1 2026, up 2.06% quarter-over-quarter from $101.8 million in Q4 2025, and up 237.0% on a YoY basis from $30.8 million in Q1 2025.
Oculis Holding AG (OCS) Cash & Equivalents (2021 - 2026) Analysis & Trends
Oculis Holding AG's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $103.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 237.0% year-over-year to $103.9 million; the TTM figure through Mar 2026 stood at $103.9 million (up 237.0% YoY), while the FY2025 annual figure was $101.8 million, up 221.72% from the prior year.
- Cash & Equivalents was $103.9 million for Q1 2026 at Oculis Holding AG, up from $101.8 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $103.9 million in Q1 2026 to a low of $20.5 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $44.7 million across 5 years, with a median of $38.5 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Cash & Equivalents slumped 59.08% in 2022, then surged 237.0% in 2026.
- A 5-year view of Cash & Equivalents shows it stood at $20.5 million in 2022, then grew by 8.61% to $22.3 million in 2023, then jumped by 41.8% to $31.6 million in 2024, then soared by 221.72% to $101.8 million in 2025, then increased by 2.06% to $103.9 million in 2026.
- The last three Cash & Equivalents figures came in at $103.9 million (Q1 2026), $101.8 million (Q4 2025), and $34.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 558.94 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 103.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.86 Mn |
| Dec 31, 2025 | 101.76 Mn |
| Sep 30, 2025 | 34.64 Mn |
| Jun 30, 2025 | 77.63 Mn |
| Mar 31, 2025 | 30.82 Mn |
| Dec 31, 2024 | 31.63 Mn |
| Sep 30, 2024 | 44.24 Mn |
| Jun 30, 2024 | 42.38 Mn |
| Mar 31, 2024 | 43.91 Mn |
| Dec 31, 2023 | 22.31 Mn |
| Sep 30, 2023 | 22.40 Mn |
| Jun 30, 2023 | 22.01 Mn |
| Mar 31, 2023 | 21.39 Mn |
| Dec 31, 2022 | 20.54 Mn |
| Sep 30, 2022 | 47.92 Mn |
| Jun 30, 2022 | 48.05 Mn |
| Dec 31, 2021 | 50.19 Mn |